InsiderDB

Lobbying disclosures · Lobbying report

MDGL: third_quarter 2026 lobbying report

Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs. Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); GENEROUS Medicaid Drug Pricing Model.

Follow MDGL
Became public
Oct 19, 2026, 11:29 AM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 7:49 AM EST

Why this is connected

Exact legal-name match: MADRIGAL PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/1157601/).

Reported lobbying amounts

Income: $50,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/2aec0cc4-8b6c-4885-ba72-631e000c14af/","filing_uuid":"2aec0cc4-8b6c-4885-ba72-631e000c14af","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/2aec0cc4-8b6c-4885-ba72-631e000c14af/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Mathew Lapinski","dt_posted":"2026-10-19T11:29:12-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 North Capitol Street, NW, Suite 800","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":400531586,"url":"https://lda.gov/api/v1/registrants/400531586/","house_registrant_id":null,"name":"CROSSROADS STRATEGIES, LLC","description":"lobbying firm","address_1":"800 North Capitol Street, NW, Suite 800","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MATHEW LAPINSKI","contact_telephone":"+1 202-559-0170","dt_updated":"2026-07-30T15:56:39.212913-04:00"},"client":{"id":68999,"url":"https://lda.gov/api/v1/clients/68999/","client_id":68999,"name":"MADRIGAL PHARMACEUTICALS, INC.","general_description":"biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-07-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen","new":true},{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); GENEROUS Medicaid Drug Pricing Model.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58561,"prefix":null,"prefix_display":null,"first_name":"MATHEW","nickname":null,"middle_name":null,"last_name":"LAPINSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143773,"prefix":"ms","prefix_display":"MS.","first_name":"CHERYL","nickname":null,"middle_name":"LYNN","last_name":"JAEGER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66496,"prefix":null,"prefix_display":null,"first_name":"JASON","nickname":null,"middle_name":"BENJAMIN","last_name":"VAN PELT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151117,"prefix":"mr","prefix_display":"MR.","first_name":"STEPHEN","nickname":null,"middle_name":"THOMAS","last_name":"VOLJAVEC","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107303,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":"JOHNSON","last_name":"HERNANDEZ","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in MDGL

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.